FDA orders vision-loss risk warnings for GLP-1 drugs
publishers 50articles 53first reported 9 Nov, 16:45 UTCdeveloping since 9 Nov · 8 editions
The U.S. Food and Drug Administration is requiring makers of GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, to add warnings about a potential increased risk of a rare eye condition that can cause permanent vision loss.
The condition, non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to the optic nerve decreases. It can cause sudden, painless loss of vision, usually in one eye. The FDA said patients who have previously experienced NAION face an increased risk.
The agency said its decision followed a review of clinical trials, observational studies and other evidence, including research published in 2024 that prompted further investigation. An FDA analysis of 126 randomized controlled trials found 6.4 NAION cases per 100,000 person-years among patients treated with GLP-1 drugs, compared with 3.8 cases among those receiving a placebo or a non-GLP-1 glucose-lowering medicine.
The findings indicate a possible association but do not establish that GLP-1 medicines cause NAION. Novo Nordisk, which makes Ozempic and Wegovy, said available research does not establish a causal link.
The FDA directed manufacturers to add the potential risk to the Warnings and Precautions section of product labels. It also said health-care providers should consider advising patients to stop GLP-1 treatment if signs of NAION develop, unless the benefits clearly outweigh the risk.
HOW THIS STORY WAS MADE
Written from 8 articles, 3 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 72 h after the record first saw the story; the editor kept it as written.
- Publishers
- 50
- Source articles
- 53
- Given to the writer
- 8, 3 with the article's own text
- Independent newsrooms
- 8
- This version written
- 72 h after the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
WHAT THE EDITOR DID
The second model checked the writer's draft against the same sources and published it as written.
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →